Activist investor Starboard Value says it will oppose Bristol-Myers’ $74 billion deal for Celgene

Health, Fitness & Food

Activist investor Starboard Value said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose the drug-maker’s acquisition of Celgene.

Bristol-Myers acquisition in a release on Wednesday.

Wellington said that it “does not believe that the Celgene transaction is an attractive path towards” business that “secures differentiated science and broadens the future revenue base.”

This story is developing. Please check back for updates.

Products You May Like

Leave a Reply

Your email address will not be published.